Est. 2001·3,000+ placements · six offices · four regions

Company signals · Biotech & Pharma

BioNTech

1 signal in the current window, with MitchelLake's leadership read on each.

Last updated

Market context: The wider read — a Talent Market Index of 95.4 (Cool), down 5.3 month-on-month — shows EMEA signal flow rising (+5pts).

BioNTech: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 30 tracked companies.

Signals at BioNTech

Executive hires, departures and board changes at BioNTech

Every leadership-change and senior-hiring signal observed at BioNTech, newest first, each dated and linked to the source record.

BioNTech signals in the last 90 days

1 public signal observed since 19 August 2026, by type.

More signals across Biotech & Pharma

Leadership Change · EMEA

Harbour BioMed →

Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.

Leadership Change · EMEA

BioMarin Pharmaceutical Inc. →

Ian T. Clark elected as new Chair of the Board, replacing retiring Richard A. Meier

Capital Raising · EMEA

Neobe Therapeutics →

UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.

Capital Raising · EMEA

mbiomics →

mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).

Geographic Expansion · EMEA

Bio-Techne →

Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.

Product Launch · EMEA

AviadoBio →

AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.

Where BioNTech's market lands in our work

Weekly briefing

Track companies like BioNTech — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record

MitchelLake is a global executive search and advisory firm covering AI, innovation and expansion leadership for companies navigating transformation and change across industries, from startups and scale-ups to private-equity-backed and enterprise organisations. 3,000+ C-suite, specialist and board placements since 2001.

Data period
13 Nov 2026 – 13 Nov 2026 · 1 signals for this company
Publisher
MitchelLake

Last updated